扶正消癌Ⅰ号方联合OFL方案治疗中晚期胃癌的临床观察  

Clinical Observation of Fuzheng Xiao'ai PrescriptionⅠCombined with OFL Regimen for Treatment of Advanced Gastric Carcinoma

作　　者：胡艳[1] 侯安继[1] 张红卫[1] 黄燕莉[1] 顾魏峰[1] 

机构地区：[1]上海市第七人民医院肿瘤科,上海200137

出　　处：《新中医》2011年第2期104-106,共3页New Chinese Medicine

基　　金：上海市浦东新区中医中青年骨干培养基金资助课题(编号:PWZ2008-20-q06)

摘　　要：目的:观察扶正消癌Ⅰ号方对OFL方案治疗中晚期胃癌的减毒增效作用。方法:将60例患者随机分为2组各30例,对照组单纯采用OFL方案化疗,治疗组在对照组治疗的基础上给予扶正消癌Ⅰ号方。治疗3周为1疗程,治疗3疗程后评价近期疗效、毒副反应、生活质量和中医辨证分型疗效。结果:近期疗效治疗组为50.00%,对照组为43.33%,2组近期疗效比较,差异无显著性意义(P>0.05);毒性反应发生率、生活质量改善情况、中医辨证分型疗效2组分别比较,差异均有显著性意义(P<0.05)。结论:扶正消癌Ⅰ号方联合OFL方案治疗中晚期胃癌能显著降低毒副反应发生率,提高患者生活质量,显著改善中医临床症状,具有肯定的减毒增效作用。Objective： To investigate the toxicity-reducing and efficacy-enhancing actions of Fuzheng Xiao＇ai Prescription I combined with OFL regimen on advanced gastric carcinoma. Methods： Sixty advanced gastric carcinoma patients were equally randomized into the treatment group and the control group. The two groups received OFL regimen, and the treatment group was treated with Fuzheng Xiao＇ai Prescription I additionally. Three weeks constituted one treatment course, and the treatment lasted 3 courses. The short-term efficacy, the toxic and side effects, quality of life （QOL） and efficacy on syndromes in traditional Chinese medicine （TCM） were assessed in both groups after treatment. Results： The short-term efficacy was 50.00% in the treatment group and 43.33% in the control group, the difference being not significant （P 〉 0.05）. The differences of the incidence of toxic and side effects, QOL, and efficacy on syndromes were significant between two groups （P 〈 0.05）. Conclusion： Fuzheng Xiao＇ai Prescription I combined with OFL regimen exerts certain toxicity-reducing and efficay- enhancing actions on advanced gastric carcinoma through reducing toxic and side effects, improving QOL, and relieving symptoms markedly.

关 键 词：胃癌 中西医结合疗法 化学疗法 扶正消癌I号方 

分 类 号：R735.2[医药卫生—肿瘤]